Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma?

Cetin B., Berk V., Kaplan M. A., Afsar B., Tufan G., Ozkan M., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.11, sa.2, ss.141-148, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.clgc.2012.09.001
  • Dergi Adı: CLINICAL GENITOURINARY CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.141-148
  • Anahtar Kelimeler: Metastatic renal cell carcinoma, VEGF-targeted therapy, Neutrophil to lymphocyte ratio, Tyrosine kinase inhibitor, PROGRESSION FREE SURVIVAL, INTERFERON-ALPHA, ELEVATED NEUTROPHIL, PREDICTS SURVIVAL, DOUBLE-BLIND, SUNITINIB, MELANOMA, EFFICACY, CANCER, BLOOD
  • Gazi Üniversitesi Adresli: Evet

Özet

In this study, we have undertaken a retrospective review of 100 patient charts to investigate whether neutrophil to lymphocyte ratio (NLR) is associated with progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients treated with second-line vascular endothelial growth factor (VEGF) targeted tyrosine kinase inhibitors (TKIs) after failure of interferon-alpha. We have shown that NLR at diagnosis is an independent predictor of survival in mRCC patients. Investigation of therapies which harness the immune response are warranted in this disease.